Does Rallies show Form 4 insider transactions for NUTX?

Yes. Rallies tracks NUTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NUTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NUTX. It does not provide personalized investment advice.

NUTX (Nutex Health Inc. Common Stock) Stock Analysis - Insider Trades

Nutex Health Inc. Common Stock (NUTX) is a publicly traded Healthcare sector company. As of May 21, 2026, NUTX trades at $121.54 with a market cap of $858.10M and a P/E ratio of 10.88. NUTX moved -3.70% today. Year to date, NUTX is -27.50%; over the trailing twelve months it is -31.41%. Its 52-week range spans $17.66 to $193.07. Analyst consensus is buy with an average price target of $237.50. Rallies surfaces NUTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NUTX stock inside the company?

Recent NUTX insider activity includes Jaumot Frank E bought 150, Hosseinion Warren bought 252, Spears Kelvin bought 10, Montgomery Pamela W. bought 79, and Bates Jon Christian bought 750. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NUTX Key Metrics

Key financial metrics for NUTX
Metric	Value
Price	$121.54
Market Cap	$858.10M
P/E Ratio	10.88
EPS	$11.13
Dividend Yield	0.00%
52-Week High	$193.07
52-Week Low	$17.66
Volume	0
Avg Volume	0
Revenue (TTM)	$875.26M
Net Income	$180.36M
Gross Margin	50.76%

Recent NUTX Insider Trades

Jaumot Frank E bought 150 (~$14.03K) on Mar 20, 2026.
Hosseinion Warren bought 252 (~$23.71K) on Mar 19, 2026.
Spears Kelvin bought 10 (~$944.6) on Mar 17, 2026.
Montgomery Pamela W. bought 79 (~$7.02K) on Mar 13, 2026.
Bates Jon Christian bought 750 (~$102.53K) on Nov 25, 2025.

Latest NUTX News

Nutex Health Q1 Revenue Up 2.2% to $216.5M; EPS Hits $6.52 — Apr 30, 2026
Nutex Health Q4 Revenue Falls 41% on $55M Arbitration True-Up — Mar 6, 2026
Nutex Health revenue leaps 82.4% to $875.3M, launches second buyback — Mar 6, 2026

NUTX Analyst Consensus

2 analysts cover NUTX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $237.50.

Common questions about NUTX

Who is trading NUTX stock inside the company?: Recent NUTX insider activity includes Jaumot Frank E bought 150, Hosseinion Warren bought 252, Spears Kelvin bought 10, Montgomery Pamela W. bought 79, and Bates Jon Christian bought 750. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NUTX?: Yes. Rallies tracks NUTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NUTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NUTX. It does not provide personalized investment advice.